US Stem Cell Inc (USRM)

[Dragon Lady]

EXPENSES, EXPENSES, EXPENSES and CUTTING R&D SPENDING-

Quote, "Revenue revenue revenue.
Revenue is a specific thing.
They increased their revenue.
No matter how you spin it, you can't deny the straight fact that Bioheart's revenues have increased quarter after quarter, and more so than ever before. "

Yes, "revenue is a specific thing" and it's not "cash" to a company, not until cost of sales and expenses are accounted for. Expenses matter as much, if not more than top-line "revenues".

What can't be denied is that expenses increased far more than the bottom line "revenues" and thus the LOSS FROM OPERATIONS found in the last 10-Q filing was GREATER in 2014, than in 2013, despite the ole "revenues".

AND, all that greater loss occurred at the same time R&D spending (the supposed key to a "medical research and development" company) all while their R&D spending was hacked to near zero.

No matter how you spin it, you can't deny the straight fact that Bioheart is spending almost nothing on R&D (aka trials) qtr over qtr while their general and admin costs/expenses have increased qtr over qte, and more so than ever in their recent history. (SEE SEC FILINGS, most recent 10-Q, period ended Sept 30, 2014 for starters).



That's PAGE 5, "condensed statement of operations" latest BHRT SEC filed 10-Q, period ending Sept 30th, 2014. Just the FACTS as found on their own financial statements. Ya can't "spin" those or "out talk" um in great sounding one-liners like "revenues increased". There's way, way, way more to running and managing a business and making it profitable than "revenues". Expense control is probably rated as more important than even "revenues" to a successful, profitable business - as run away expenses have sunk and killed more businesses probably than "revenue problems" ever have IMO.